Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07674394

New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.

Liver transplantation is a life-saving treatment for patients with severe liver disease. Because of the shortage of donor organs, transplant centers increasingly use donor livers that may be more vulnerable to injury and dysfunction. To improve the quality of these organs before transplantation, many centers use hypothermic oxygenated machine perfusion (HOPE or D-HOPE), a technique that preserves the liver under cold, oxygenated conditions. However, there are currently no widely accepted methods to determine whether a liver is functioning well enough during this preservation process.

The purpose of this study is to investigate whether changes observed in liver tissue during hypothermic machine perfusion can help predict how well the transplanted liver will function after surgery. The study will compare liver biopsy samples collected before and after one hour of perfusion and will analyze biological markers released into the perfusion fluid, including markers of mitochondrial injury and inflammation.

The main question this study aims to answer is whether histological changes occurring during hypothermic perfusion, alone or in combination with biochemical biomarkers, can accurately predict liver graft viability and post-transplant outcomes. Researchers will also evaluate whether these data can be used to develop an artificial intelligence-based model to support clinical decision-making during organ preservation.

A total of 150 adult liver transplant recipients receiving donor livers treated with HOPE or D-HOPE will be enrolled at three Italian liver transplant centers. Participants will be followed for 90 days after transplantation to assess liver graft function, graft survival, patient survival, and post-transplant complications.

The results of this study may improve the assessment of donor liver quality before transplantation and help clinicians make more informed decisions about organ use, ultimately increasing the safety and effectiveness of liver transplantation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult liver transplant recipients (≥18 years of age).
  • Donor liver grafts from either Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD).
  • Grafts undergoing hypothermic oxygenated perfusion (HOPE) (HOPE or D-HOPE) for a minimum duration of 1 hour prior to transplantation.
  • Availability of two wedge liver biopsy samples: one pre perfusion and one post-perfusion.
  • Grafts preserved using standard cold storage protocols and transported in ice-cold Servator C™ solution.
  • Informed consent obtained from the recipient (or legal representative, where applicable) for the use of clinical and histological data for research purposes.

Exclusion criteria

  • Inadequate or fragmented biopsy samples, preventing proper histological evaluation.
  • Biopsy samples showing histological features of pre-existing chronic liver disease (e.g., cirrhosis, autoimmune hepatitis, chronic viral hepatitis).
  • Liver grafts subjected to normothermic perfusion or other non hypothermic perfusion techniques.
  • Organs undergoing experimental or non-standard perfusion protocols.
  • Grafts from donors <18 years of age.
  • Recipient refusal or inability to provide informed consent.
  • Technical failure during perfusion (e.g., incomplete perfusion due to device malfunction or vascular anomalies).
  • Known malignancy in the donor with potential liver involvement, excluding donors with small incidentalomas as per standard guidelines.

Treatment and study plan

Hypothermic Oxygenated Machine Perfusion (HOPE/D-HOPE)

Procedure

Standard-of-care hypothermic oxygenated machine perfusion of donor liver grafts before transplantation, with collection of biopsies and perfusate samples for research analyses.

Primary outcomes

  1. Graft Survival

    Time frame: 90 days after liver transplantation

    Graft survival defined as the absence of Early Allograft Dysfunction (EAD) or Primary Non-Function (PNF) following liver transplantation. Histological changes observed between pre-perfusion and post-perfusion liver biopsies will be evaluated for their association with graft outcomes.

Study contacts

Contact information is provided by the study sponsor or research team.

Ivan Vella

CONTACT

[email protected]

+39 3803403369

Monica Rizzo

CONTACT

[email protected]

+39 0912192692

Sponsors and collaborators

Lead sponsor

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

Other

Registry information

Acronym: LOVE

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.